Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph T Opferman

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Molecular Cell|March 3, 2018
Dynamic Regulation of Long-Chain Fatty Acid Oxidation by a Noncanonical Interaction between the MCL-1 BH3 Helix and VLCADSilvia Escudero, Elma Zaganjor, Susan Lee, et al.
Cell|September 25, 2018
LC3-Associated Phagocytosis in Myeloid Cells Promotes Tumor Immune ToleranceLarissa D Cunha, Mao Yang, Robert Carter, et al.
Nature Cell Biology|September 26, 2017
Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressorXiaofeng Wu, Li-Shu Zhang, Jason Toombs, et al.
Cell Death & Disease|June 25, 2026
Mitochondrial integrated stress response activation creates a therapeutic vulnerability to MCL-1 inhibition in acute myeloid leukemiaLauren Brakefield-Laird, Amit Budhraja, Peter M Hall, et al.
Communications Biology|December 22, 2025
Mitochondrial proteostasis regulated by CRL5<sup>Ozz</sup> and Alix modulates skeletal muscle metabolism and fiber typeYvan Campos, Gustavo Palacios, Elida Gomero, et al.
The Lancet. Oncology|March 15, 2020
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation studySeth E Karol, Thomas B Alexander, Amit Budhraja, et al.
The Lancet. Haematology|July 8, 2026
Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion studyKatelyn P Daniels, Stanley B Pounds, Huiyun Wu, et al.
Pediatric Blood & Cancer|March 10, 2025
Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaAndrew E Place, Seth E Karol, Christopher J Forlenza, et al.
Blood|January 10, 2025
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemiaCarolin S Escherich, Takaya Moriyama, Zhenhua Li, et al.
Blood|August 14, 2025
Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemiaLindsey E Montefiori, Ilaria Iacobucci, Qingsong Gao, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Molecular Cell|March 3, 2018
Dynamic Regulation of Long-Chain Fatty Acid Oxidation by a Noncanonical Interaction between the MCL-1 BH3 Helix and VLCADSilvia Escudero, Elma Zaganjor, Susan Lee, et al.
Cell|September 25, 2018
LC3-Associated Phagocytosis in Myeloid Cells Promotes Tumor Immune ToleranceLarissa D Cunha, Mao Yang, Robert Carter, et al.
Nature Cell Biology|September 26, 2017
Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressorXiaofeng Wu, Li-Shu Zhang, Jason Toombs, et al.
Cell Death & Disease|June 25, 2026
Mitochondrial integrated stress response activation creates a therapeutic vulnerability to MCL-1 inhibition in acute myeloid leukemiaLauren Brakefield-Laird, Amit Budhraja, Peter M Hall, et al.
Communications Biology|December 22, 2025
Mitochondrial proteostasis regulated by CRL5<sup>Ozz</sup> and Alix modulates skeletal muscle metabolism and fiber typeYvan Campos, Gustavo Palacios, Elida Gomero, et al.
The Lancet. Oncology|March 15, 2020
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation studySeth E Karol, Thomas B Alexander, Amit Budhraja, et al.
The Lancet. Haematology|July 8, 2026
Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion studyKatelyn P Daniels, Stanley B Pounds, Huiyun Wu, et al.
Pediatric Blood & Cancer|March 10, 2025
Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaAndrew E Place, Seth E Karol, Christopher J Forlenza, et al.
Blood|January 10, 2025
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemiaCarolin S Escherich, Takaya Moriyama, Zhenhua Li, et al.
Blood|August 14, 2025
Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemiaLindsey E Montefiori, Ilaria Iacobucci, Qingsong Gao, et al.
Pageof 8